Canada moves closer to expanded access to multiple myeloma treatment
New national agreement could expand public funding for a four-drug treatment shown to delay disease progression in eligible patients.
A new agreement between Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) could expand publicly funded treatment options for Canadians diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow.
Announced November 16, the agreement covers Sarclisa (isatuximab), used in combination with bortezomib, lenalidomide and dexamethasone. The four-drug regimen is intended for adults with newly diagnosed multiple myeloma who are not eligible for stem cell transplantation.
The agreement represents an important step toward expanded access, although provincial and territorial drug plans must still make their funding decisions.
Clinical evidence supports treatment approach
The agreement follows results from the international Phase 3 IMROZ clinical trial involving 446 patients.
At approximately five years of follow-up, 63.2 per cent of patients receiving the four-drug combination remained free from disease progression, compared with 45.2 per cent receiving the standard three-drug treatment.
The addition of isatuximab was associated with a 40 per cent relative reduction in the risk of disease progression or death during the study period.
Published in The New England Journal of Medicine, the findings also demonstrated higher rates of complete response and deeper disease control. However, a statistically significant overall survival benefit had not been established at the time of the reported analysis. Treatment also requires monitoring for adverse effects, including infections.
An important milestone for Canadian cancer care
Multiple myeloma is Canada’s second most common blood cancer, with approximately 4,400 new cases expected in 2026.
The disease affects the bone marrow and can cause anemia, bone damage, kidney complications and increased susceptibility to infections.
For patients who are ineligible for transplantation because of age or other medical considerations, maintaining disease control is a major treatment objective.
Canada’s Drug Agency recommended public reimbursement of the isatuximab combination in June 2025, subject to specified conditions. The new pCPA agreement brings the treatment another step closer to public coverage.
Next steps toward public coverage
While the national agreement establishes negotiated terms, it does not automatically provide public reimbursement. Individual provinces and territories must complete their own funding and listing decisions.
For hospital oncology teams and pharmacists, the agreement could eventually provide another first-line treatment option for eligible patients.
The development highlights the importance of translating promising clinical research into accessible cancer treatments while ensuring appropriate funding and patient care across Canada’s healthcare system.
The post Canada moves closer to expanded access to multiple myeloma treatment appeared first on Hospital News.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
